Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | EIF4E | P06730 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 7/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.33 |
| ▸ | ERBB3 | P21860 | 7/20 | 0.33 |
| ▸ | ERBB4 | Q15303 | 7/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20506184 | 0.85 | DYRK1A (0.55) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL13186164 | 0.74 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL10139171 | 0.72 | DYRK1A (0.32) | DYRK1A | |
| SCHEMBL3386908 | 0.69 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL397656 | 0.69 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL23158613 | 0.69 | DYRK1A (0.64) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL1056424 | 0.69 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL8223 | 0.69 | DYRK1A (1.00) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL2078428 | 0.69 | DYRK1A (0.59) | DYRK1AIRAK4EIF4EMKNK1MKNK2 | |
| SCHEMBL20712736 | 0.69 | MAPK1 (0.41) | DYRK1AIRAK4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| EP-3765458-B1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20120053183-A1 | PIPERAZINYLPYRIMIDINE ANALOGUES AS PROTEIN KINASE INHIBITORS | UNIVERSITY OF THE PACIFIC (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-7977340-B2 | Antibacterial compositions | PROLYSIS LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | BIOTA EUROPE LTD (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004221-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | DYRK1A 4441/4885IRAK4 4214/4885EIF4E 2537/4885 |
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | DYRK1A 2769/4885IRAK4 3276/4885EIF4E 3282/4885 |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | DYRK1A 3323/4885IRAK4 2988/4885EIF4E 4695/4885 |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP11B2, WEE2, CYP11B1 | DYRK1A 919/4885IRAK4 4445/4885EIF4E 4161/4885 |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | C5, AGK, CYCS | DYRK1A 1600/4885IRAK4 1865/4885EIF4E 1442/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | DYRK1A 3323/4885IRAK4 2988/4885EIF4E 4695/4885 |
| US-20120053183-A1 | PIPERAZINYLPYRIMIDINE ANALOGUES AS PROTEIN KINASE INHIBITORS | DCK, PAK5, CDK2 | DYRK1A 704/4885IRAK4 981/4885EIF4E 538/4885 |
| US-20110263590-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | DYRK1A 4497/4885IRAK4 4258/4885EIF4E 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.